The application of non-selective β-blockers, angiotensin receptor antagonists and statins in liver cirrhotic patients
10.3760/cma.j.issn.1007-3418.2019.12.004
- VernacularTitle: 非选择性β-受体阻滞剂、血管紧张素受体拮抗剂及他汀类药物在肝硬化患者中的应用
- Author:
Xingxin ZHANG
1
;
Jinsheng GUO
Author Information
1. Division of Digestive Diseases, Zhongshan Hospital, Shanghai Institute of Liver Diseases, Fudan University, Shanghai 200032, China
- Publication Type:Journal Article
- Keywords:
Liver cirrhosis;
Therapy;
Portal hypertension;
Non-selective β
-blockers;
Angiotensin receptor antagonists;
Statins
- From:
Chinese Journal of Hepatology
2019;27(12):923-928
- CountryChina
- Language:Chinese
-
Abstract:
Portal hypertension is the major cause of complications in decompensated liver cirrhosis. Research results showed that non-selective β-blockers, angiotensin receptor antagonists, and statins can improve portal hypertension by reducing portal vein blood flow and intrahepatic resistance, and have certain prevention and treatment effect on hemodynamic disorders and portal hypertensive complications in chronic liver diseases. Herein, we review the mechanism of action, clinical effects and limitations of these three types of drugs on portal hypertension of cirrhosis.
